Systolic and diastolic blood pressure should be controlled in patients with HFpEF in accordance with published clinical practice guidelines to prevent morbidity (28,247). (Level of Evidence: B) 2. Diuretics should be used for relief of symptoms due to volume overload in patients with HFpEF. (Level of Evidence: C) CLASS IIa 1. Coronary revascularization is reasonable in patients with CAD in whom symptoms (angina) or demonstrable myo- cardial ischemia is judged to be having an adverse effect on symptomatic HFpEF despite GDMT. (Level of Evidence: C) 2. Management of AF according to published clinical practice guidelines in patients with HFpEF is reasonable to improve symptomatic HF. (Level of Evidence: C) 3. The use of beta-blocking agents, ACE inhibitors, and ARBs in patients with hypertension is reasonable to control blood pressure in patients with HFpEF. (Level of Evidence: C) CLASS IIb 1. The use of ARBs might be considered to decrease hospitalizations for patients with HFpEF (248). (Level of Evidence: B) CLASS III: NO BENEFIT 1. Routine use of nutritional supplements is not recommended for patients with HFpEF. (Level of Evidence: C) 6.3.4. Device Therapy for Stage C HFrEF See Table 17 for a summary of recommendations from this section. CLASS I 1. ICD therapy is recommended for primary prevention of sudden cardiac death to reduce total mortality in selected patients with nonischemic dilated cardiomyopathy or ischemic heart disease at least 40 days post-MI with LVEF of 35% or less and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of mean- ingful survival for more than 1 yeary (148,249). (Level of Evidence: A) 2. 